Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP DE-2502
- Development stage
- Unknown
- Lead developer
- Daewoo Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
DWP DE-2502 is an investigational ophthalmic drug candidate currently in Phase 1 clinical development for the treatment of dry eye syndrome. Developed by the South Korean pharmaceutical company Daewoo Pharma (대우제약), the drug is part of a specialized research and development pipeline focused on ophthalmic conditions, including glaucoma, presbyopia, and myopia. While specific details regarding its active pharmaceutical ingredient and molecular target have not been publicly disclosed, it is being evaluated for its safety and efficacy in alleviating the symptoms of ocular surface disease and dry eye.
Beyond the preview
Go deeper on DWP DE-2502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP DE-2502.